Drug Index

Elvitegravir

 
print

Mechanism :

Integrase inhibitor: Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus


Indication :

• HIV-1 infection


Contraindications :

No contraindications.


Dosing :

Not specified in children.

Adults:

Administered with concomitant atazanavir and ritonavir or lopinavir and ritonavir: 85 mg once daily.

Administered with concomitant darunavir and ritonavir, fosamprenavir and ritonavir, or tipranavir and ritonavir: 150 mg once daily.


Adverse Effect :

Headache, depression, fatigue, insomnia, suicidal ideation, skin rash, diarrhea, nausea, abdominal pain, dyspepsia, vomiting, immune reconstitution syndrome.


Interaction :

Antacids: May decrease the serum concentration of Elvitegravir.
CYP3A4 Inducers: May increase the metabolism of CYP3A4 Substrates
Darunavir: May increase the serum concentration of Elvitegravir.
Dexamethasone (Systemic): May decrease the serum concentration of Elvitegravir.
Fosphenytoin-Phenytoin: May decrease the serum concentration of Elvitegravir.
Ketoconazole (Systemic): May increase the serum concentration of Elvitegravir.
Voriconazole: May increase the serum concentration of Elvitegravir.
Rifampin: May decrease the serum concentration of Elvitegravir.


07/19/2019 03:02:23 Elvitegravir
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0